Dementia and Neurocognitive Disorders (대한치매학회지)

Korean Dementia Association (대한치매학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of GV1001 on Language Dysfunction in Patients With Moderate-to-Severe Alzheimer's Disease: Post Hoc Analysis of Severe Impairment Battery Subscales

  • Hyuk Sung Kwon (Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine) ;
  • Seong-Ho Koh (Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine) ;
  • Seong Hye Choi (Department of Neurology, Inha University School of Medicine) ;
  • Jee Hyang Jeong (Department of Neurology, Ewha Womans University College of Medicine) ;
  • Hae Ri Na (Department of Neurology, Bobath Memorial Hospital) ;
  • Chan Nyoung Lee (Department of Neurology, Korea University Anam Hospital) ;
  • YoungSoon Yang (Department of Neurology, Soonchunhyang University Cheonan Hospital) ;
  • Ae Young Lee (Department of Neurology, Chungnam National University Hospital) ;
  • Jae-Hong Lee (Department of Neurology, Asan Medical Center) ;
  • Kyung Won Park (Department of Neurology, Dong-A University Hospital) ;
  • Hyun Jeong Han (Department of Neurology, Myongji Hospital, Hanyang University College of Medicine) ;
  • Byeong C. Kim (Department of Neurology, Chonnam National University Medical School and Hospital) ;
  • Jinse Park (Department of Neurology, Haeundae Paik Hospital, Inje University) ;
  • Jee-Young Lee (Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center) ;
  • Kyu-Yong Lee (Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine) ;
  • Sangjae Kim (Teloid Inc.)
  • Received : 2023.06.15
  • Accepted : 2023.06.22
  • Published : 2023.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background and Purpose: The efficacy and safety of GV1001 have been demonstrated in patients with moderate-to-severe Alzheimer's disease (AD). In this study, we aimed to further demonstrate the effectiveness of GV1001 using subscales of the Severe Impairment Battery (SIB), which is a validated measure to assess cognitive function in patients with moderate-to-severe AD. Methods: We performed a post hoc analysis of data from a 6 month, multicenter, phase 2, randomized, double-blind, placebo-controlled trial with GV1001 (ClinicalTrials.gov, NCT03184467). Patients were randomized to receive either GV1001 or a placebo for 24 weeks. In the current study, nine subscales of SIB-social interaction, memory, orientation, language, attention, praxis, visuospatial ability, construction, and orientation to name-were compared between the treatment (GV1001 1.12 mg) and placebo groups at weeks 12 and 24. The safety endpoints for these patients were also determined based on adverse events. Results: In addition to the considerable beneficial effect of GV1001 on the SIB total score, GV1001 1.12 mg showed the most significant effect on language function at 24 weeks compared to placebo in both the full analysis set (FAS) and per-protocol set (PPS) (p=0.017 and p=0.011, respectively). The rate of adverse events did not differ significantly between the 2 groups. Conclusions: Patients with moderate-to-severe AD receiving GV1001 had greater language benefits than those receiving placebo, as measured using the SIB language subscale.

Keywords

Acknowledgement

This research was supported by grants from the Korea Dementia Research Center (KDRC) funded by the Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea (HI20C0253, HU21C0113, and HU21C0007), and GemVax & Kael Co., Ltd.

References

  1. Li X, Feng X, Sun X, Hou N, Han F, Liu Y. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2019. Front Aging Neurosci 2022;14:937486.
  2. Koh SH, Kwon HS, Choi SH, Jeong JH, Na HR, Lee CN, et al. Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer's disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. Alzheimers Res Ther 2021;13:66.
  3. Farlow MR, Miller ML, Pejovic V. Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. Dement Geriatr Cogn Disord 2008;25:408-422.
  4. Ghezzi L, Scarpini E, Galimberti D. Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther 2013;7:1471-1478.
  5. Cummings J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer's disease therapeutics. Drugs 2023;83:569-576.
  6. Park HH, Lee KY, Park DW, Choi NY, Lee YJ, Son JW, et al. Tracking and protection of transplanted stem cells using a ferrocenecarboxylic acid-conjugated peptide that mimics hTERT. Biomaterials 2018;155:80-91.
  7. Park HH, Yu HJ, Kim S, Kim G, Choi NY, Lee EH, et al. Neural stem cells injured by oxidative stress can be rejuvenated by GV1001, a novel peptide, through scavenging free radicals and enhancing survival signals. Neurotoxicology 2016;55:131-141.
  8. Saxton J, McGonigle-Gibson KL, Swihart AA, Miller VJ, Boller F. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. Psychol Assess 1990;2:298-303.
  9. Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11 Suppl 2:S51-S56.
  10. Ferris S, Ihl R, Robert P, Winblad B, Gatz G, Tennigkeit F, et al. Severe Impairment Battery Language scale: a language-assessment tool for Alzheimer's disease patients. Alzheimers Dement 2009;5:375-379.
  11. Ferris SH, Schmitt FA, Saxton J, Richardson S, Mackell J, Sun Y, et al. Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease. Alzheimers Res Ther 2011;3:22.
  12. Ferris S, Ihl R, Robert P, Winblad B, Gatz G, Tennigkeit F, et al. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients. Alzheimers Dement 2009;5:369-374.
  13. Ferris S, Karantzoulis S, Somogyi M, Meng X. Rivastigmine in moderately severe-to-severe Alzheimer's disease: Severe Impairment Battery factor analysis. Alzheimers Res Ther 2013;5:63.
  14. Mecocci P, Bladstrom A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry 2009;24:532-538.
  15. Savundranayagam MY, Hummert ML, Montgomery RJ. Investigating the effects of communication problems on caregiver burden. J Gerontol B Psychol Sci Soc Sci 2005;60:S48-S55.
  16. Hendryx-Bedalov PM. Alzheimer's dementia. Coping with communication decline. J Gerontol Nurs 2000;26:20-24.
  17. Henry JD, Crawford JR, Phillips LH. Verbal fluency performance in dementia of the Alzheimer's type: a meta-analysis. Neuropsychologia 2004;42:1212-1222.
  18. Ferrell BA. Pain evaluation and management in the nursing home. Ann Intern Med 1995;123:681-687.
  19. Tsai PF, Chang JY. Assessment of pain in elders with dementia. Medsurg Nurs 2004;13:364-369, 390.
  20. Schmitt FA, Cragar D, Ashford JW, Reisberg B, Ferris S, Mobius HJ, et al. Measuring cognition in advanced Alzheimer's disease for clinical trials. J Neural Transm Suppl 2002;62:135-148.
  21. Burns A, Bernabei R, Bullock R, Cruz Jentoft AJ, Frolich L, Hock C, et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol 2009;8:39-47.
  22. Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin J. Reviews: effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen 2010;25:627-633.
  23. Klimova B, Maresova P, Valis M, Hort J, Kuca K. Alzheimer's disease and language impairments: social intervention and medical treatment. Clin Interv Aging 2015;10:1401-1407.